TrialThe Journal of international medical research2019

A phase II study of the combination of docetaxel and bevacizumab for previously treated non-small cell lung cancer.

Tetsuo Shimizu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.